FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia

FDA Approves First Gene Therapy for GSDIa

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Genglycos (pariglasgene brecaparvovec-opnr) for adults and pediatric patients aged 8 years and older with glycogen storage disease type Ia (GSDIa). This gene therapy is the first approved treatment for the rare, inherited genetic disorder, intended to reduce daily cornstarch intake as an adjunct to nutritional management. The approval was based on clinical trial data showing a statistically significant mean reduction of 31% in daily cornstarch intake, which served as a surrogate endpoint. The manufacturer is required to conduct additional clinical trials to confirm Genglycos’s long-term effectiveness.

• Glycogen Storage Disease Type Ia (GSDIa) is a rare, inherited genetic disorder caused by a deficiency of the glucose-6-phosphatase enzyme, leading to dangerously low blood sugar. Patients face possible life-threatening complications and rely on strict, lifelong dietary management, including daily cornstarch supplementation, highlighting a significant unmet medical need for effective treatments.
• Genglycos is a one-time AAV8 based gene therapy designed to deliver a functional G6PC gene to the liver, aiming to restore the deficient enzyme required to release stored glucose and ensure stable blood sugar levels. Its accelerated approval was based on clinical trial data demonstrating a statistically significant 31% mean reduction in daily cornstarch intake, a surrogate endpoint, with confirmatory trials required.
• In a randomized, double-blind, placebo-controlled study, Genglycos-treated patients achieved a 31% mean reduction from baseline in daily cornstarch intake, the primary endpoint, and a mean reduction of one cornstarch dose per day compared to placebo, the secondary endpoint. Serious adverse reactions included anaphylaxis, adrenal insufficiency, high lactate levels, and hypoglycemia, with common reactions like increased transaminases, nausea, and headache.

Addressing the Unmet Need in Glycogen Storage Disease Type Ia

Current treatment strategies for GSDIa primarily rely on dietary management with uncooked cornstarch to prevent life-threatening hypoglycemia, yet this approach is associated with significant patient burden and incomplete disease control. Despite extending survival, these interventions fail to prevent a spectrum of serious long-term complications, and emerging gene therapy approaches face their own technical and translational hurdles.

• Dietary management limitations: Uncooked cornstarch remains the cornerstone of therapy but can cause hyperglycemia and weight gain, while nighttime glucose control remains particularly difficult to achieve consistently. Extended-release cornstarch formulations offer clinically meaningful improvements but are considerably more expensive than standard cornstarch, raising cost-effectiveness concerns.

• Long-term organ complications: Even with optimized dietary therapy, most patients develop chronic pathologies including renal disease, gout, osteoporosis, and pulmonary hypertension. Hepatocellular adenoma (HCA) develops in 22–75% of patients during the second or third decade of life, with a subset undergoing malignant transformation to hepatocellular carcinoma.

• Transgene durability in AAV-based gene therapy: Although AAV-mediated gene replacement has achieved proof of concept and entered clinical trials, episomal vector genomes experience gradual transgene loss over time — likely linked to hepatocyte degeneration underlying GSDIa pathophysiology and hepatic tumor development. This has necessitated re-administration using alternative AAV pseudotypes in canine models, and long-term durability of expression in humans remains to be established.

• Multitissue targeting requirements: Achieving therapeutic correction across all affected tissues — including metabolically relevant non-hepatic tissues such as muscle and kidney — requires high vector doses to transduce these less permissive targets, compounding safety and manufacturing challenges for gene therapy approaches.

Understanding the Genetic Roots of GSDIa

Glycogen Storage Disease Type Ia (GSDIa) is caused by a deficiency of glucose-6-phosphatase-α (G6Pase-α), encoded by the G6PC1 gene, which catalyzes the terminal step of both gluconeogenesis and glycogenolysis within the endoplasmic reticulum lumen. Inactivating mutations in G6PC1 disrupt the structural integrity of the enzyme's active site, where conserved residues from the signature phosphatidic acid phosphatase motif normally sustain a hydrogen bonding and van der Waals network that stabilizes glucose-6-phosphate (G6P) in the catalytic pocket. Pathogenic mutations alter this thermodynamic landscape through multiple mechanisms — including modified side chain packing, disrupted substrate-binding interactions, and trapping of catalytic intermediates — collectively impairing G6P binding energy and thermostability across several distinct pathways of catalytic failure.

At the cellular level, mitochondrial dysfunction is a central driver of disease pathogenesis. Cell culture, murine, and canine models of GSDIa consistently demonstrate impaired oxidative phosphorylation, derangements in TCA cycle metabolites, reduced mitochondrial membrane potential, and structural disruption of mitochondrial architecture. Mitochondrial content is diminished, attributable to decreased mitochondrial biogenesis, and these compounding defects ultimately activate the mitochondrial apoptosis pathway. Concurrent autophagy impairment — documented across multiple model systems — further exacerbates cellular dysfunction, driven by stimulation of the anti-autophagic mTOR pathway and suppression of the pro-autophagic AMPK pathway, both in vitro and in vivo.

The downstream metabolic consequences of G6Pase-α deficiency stem from the liver's reduced capacity to convert G6P to free glucose, leading to progressive accumulation of glycogen and lipid within hepatocytes. This metabolic burden drives a pathological continuum from hepatomegaly and steatohepatitis through cirrhosis, ultimately culminating in the formation of hepatic adenomas and the potential for malignant transformation to hepatocellular carcinoma — reflecting the systemic severity that underlies GSDIa's clinical course.

Genglycos's Clinical Evidence: Design and Key Endpoints

Clinical evidence in GSDIa spans gene therapy, dietary intervention, and natural history research, collectively informing both mechanistic understanding and therapeutic benchmarking. The trials described below vary in design complexity — from open-label dose-escalation studies to randomized crossover pilots — but share a focus on metabolic stabilization, hypoglycemia prevention, and long-term hepatic outcomes.

First Gene Therapy for GSDIa: Hope and Hurdles

The recent accelerated approval of Genglycos (pariglasgene brecaparvovec-opnr) for glycogen storage disease type Ia (GSDIa) marks a pivotal moment for patients and the broader gene therapy landscape. For decades, individuals with GSDIa have relied on a rigorous regimen of uncooked cornstarch and strict dietary management to prevent life-threatening hypoglycemia and manage a host of metabolic complications, including hyperlipidemia and the risk of liver tumors. This daily burden significantly impacts quality of life, and despite best efforts, the current approach is imprecise and does not address the root cause of the disease: a defective glucose-6-phosphatase (G6Pase) enzyme.

Genglycos, as the first approved gene therapy for GSDIa, offers the promise of restoring endogenous G6Pase function, potentially liberating patients from the constant vigilance of cornstarch intake. Clinical trial data, including patient experience interviews, have shown substantial reductions in cornstarch intake and reported improvements in symptoms, physical function, and overall health-related quality of life. This represents a significant step towards a disease-modifying treatment that could fundamentally alter the trajectory of GSDIa.

However, this groundbreaking approval comes with inherent considerations. As an accelerated approval, Genglycos's long-term effectiveness must be confirmed through additional clinical trials. The durability of gene therapy is a critical factor; preclinical studies in animal models have indicated a gradual loss of transgene expression over time, raising questions about the need for potential re-administration or sustained efficacy in humans. Furthermore, while the therapy aims to correct the underlying enzyme deficiency, careful long-term monitoring will be essential to understand its full impact on secondary metabolic manifestations, such as hyperlipidemia, and the potential for liver complications like hepatocellular adenomas and carcinomas, which are inherent to GSDIa. Optimizing patient outcomes will require not only the therapy itself but also continued guidance on dietary adjustments and close metabolic monitoring. This approval underscores the immense potential of gene therapy in rare diseases, while also highlighting the ongoing need for robust post-market data to fully realize its promise.